Late kidney allograft loss: What we know about it, and what we can do about it

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue SUPPL. 2, 2008, Pages

  Jevnikar, Anthony M ^a   Mannon, Roslyn B ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; ATROPHY; DELAYED GRAFT FUNCTION; FIBROSIS; HUMAN; IMMUNOLOGY; KIDNEY; KIDNEY TRANSPLANTATION; PATHOLOGY; REVIEW;

ATROPHY; DELAYED GRAFT FUNCTION; FIBROSIS; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 41749096622     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03040707     Document Type: Article

References (134)

1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB: Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346: 580-590, 2002
2. Harris S, Coupes BM, Roberts SA, Roberts IS, Short CD, Brenchley PE: TGF-beta1 in chronic allograft nephropathy following renal transplantation. J Nephrol 20: 177-185, 2007
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333, 2003
4. Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF: International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 44: 411-422, 1993
5. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson TW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999
6. Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin NE, Williams WW, Cosimi AA, Schneeberger EE, Colvin RB: Chronic humoral rejection: Identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 12: 574-582, 2001
7. Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA: Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 5: 582-594, 2005
8. Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, Mihatsch MJ, Nickeleit V, Ramos E, Randhawa P, Shapiro R, Steiger J, Suthanthiran M, Trofe J: Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 79: 1277-1286, 2005
9. Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, Campbell PM, Cascalho M, Collins AB, Demetris AJ, Drachenberg CB, Gibson IW, Grimm PC, Haas M, Lerut E, Liapis H, Mannon RB, Marcus PB, Mengel M, Mihatsch MJ, Nankivell BJ, Nickeleit V, Papadimitriou JC, Platt JL, Randhawa P, Roberts I, Salinas-Madriga L, Salomon DR, Seron D, Sheaff M, Weening JJ: Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 7: 518-526, 2007
10. Mengel M, Chapman JR, Cosio FG, Cavaille-Coll MW, Haller H, Halloran PF, Kirk AD, Mihatsch MJ, Nankivell BJ, Racusen LC, Roberts IS, Rush DN, Schwarz A, Seron D, Stegall MD, Colvin RB: Protocol biopsies in renal transplantation: Insights into patient management and pathogenesis. Am J Transplant 7: 512-517, 2007
11. Mengel M, Gwinner W, Schwarz A, Bajeski R, Franz I, Brocker V, Becker T, Neipp M, Klempnauer J, Haller H, Kreipe H: Infiltrates in protocol biopsies from renal allografts. Am J Transplant 7: 356-365, 2007
12. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD: Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 5: 2464-2472, 2005
13. Moreso F, Ibernon M, Goma M, Carrera M, Fulladosa X, Hueso M, Gil-Vernet S, Cruzado IM, Torras J, Grinyo JM, Seron D: Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 6: 747-752, 2006
14. Shishido S, Asanuma H, Nakai H, Mori Y, Satoh H, Kamimaki I, Hataya H, Ikeda M, Honda M, Hasegawa A: The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 14: 1046-1052, 2003
15. Cosio FG, Grande JP, Larson TS, Gloor JM, Velosa JA, Textor SC, Griffin MD, Stegall MD: Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 5: 1130-1136, 2005
16. Mannon RB, Kirk AD: Beyond histology: Novel tools to diagnose allograft dysfunction. Clin J Am Soc Nephrol 1: 358-366, 2006
17. Sarwal MM: Chipping into the human genome: Novel insights for transplantation. Immunol Rev 210: 138-155, 2006
18. Schaub S, Wilkins JA, Rush D, Nickerson P: Developing a tool for noninvasive monitoring of renal allografts. Expert Rev Proteomics 3: 497-509, 2006
19. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook PJ, Novick AC: Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74: 1070-1076, 2002
20. Park W, Griffin M, Grande JP, Cosio F, Stegall MD: Molecular evidence of injury and inflammation in normal and fibrotic renal allografts one year posttransplant. Transplantation 83: 1466-1476, 2007
21. Saurina A, Campistol JM, Lario S, Oppenheimer F, Diekmann F: Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration. Transplant Proc 39: 2138-2141, 2007
22. Cheng O, Thuillier R, Sampson E, Schultz G, Ruiz P, Zhang X, Yuen PS, Mannon RB.: Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant 6: 2292-2306, 2006
23. Thuillier R, Mannon RB: The immunology of chronic allograft injury. N.l Ahsan. Eurekah Bioscience Database Chronic Allograft Failure: Natural History, Pathogenesis, Diagnosis and Management, Landes Biosciences, 2007, http://www.eurekah.com/chapter/3237
24. Csencsits K, Wood SC, Lu G, Faust SM, Brigstock D, Eichwald EJ, Orosz CG, Bishop DK: Transforming growth factor beta-induced connective tissue growth factor and chronic allograft rejection. Am J Transplant 6: 959-966, 2006
25. Mannon RB, Kopp JB, Ruiz P, Griffiths R, Bustos M, Platt JL, Klotman PE, Coffman TM: Chronic rejection of mouse kidney allografts. Kidney Int 55: 1935-1944, 1999
26. Mannon RB, Doyle C, Griffiths R, Bustos M, Platt JL, Coffman TM: Altered intragraft immune responses and improved renal function in MHC class II-deficient mouse kidney allografts. Transplantation 69: 2137-2143, 2000
27. Coupes BM, Newstead CG, Short CD, Brenchley PE: Transforming growth factor beta 1 in renal allograft recipients. Transplantation 57: 1727-1731, 1994
28. Gaciong Z, Koziak K, Religa P, Lisiecka A, Morzycka-Michalik M, Rell K, Kozlowska-Boszko B, Lao M: Increased expression of growth factors during chronic rejection of human kidney allograft. Transplant Proc 27: 928-929, 1995
29. Tikkanen JM, Koskinen PK, Lemstrom KB: Role of endogenous endothelin-1 in transplant obliterative airway disease in the rat. Am J Transplant 4: 713-720, 2004
30. Wahab NA, Mason RM: A critical look at growth factors and epithelial-to-mesenchymal transition in the adult kidney: Interrelationships between growth factors that regulate EMT in the adult kidney. Nephron Exp Nephrol 104: e129-e134, 2006
31. Melk A, Schmidt BM, Vongwiwatana A, Rayner DC, Halloran PF: Increased expression of senescence-associated cell cycle inhibitor p16INK4a in deteriorating renal transplants and diseased native kidney. Am J Transplant 5: 1375-1382, 2005
32. Pagtalunan ME, Olson JL, Tilney NL, Meyer TW: Late consequences of acute ischemic injury to a solitary kidney. J Am Soc Nephrol 10: 366-373, 1999
33. Bonegio R, Lieberthal W: Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 11: 301-308, 2002
34. Ortiz A, Lorz C, Catalan MP, Danoff TM, Yamasaki Y, Egido J, Neilson EG: Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. Kidney Int 57: 969-981, 2000
35. Ortiz A: Nephrology forum: Apoptotic regulatory proteins in renal injury. Kidney Int 58: 467-485, 2000
36. Du C, Guan Q, Yin Z, Masterson M, Zhong R, Jevnikar AM: Renal tubular epithelial cell apoptosis by Fas-FasL-dependent self-injury can augment renal allograft injury. Transplant Proc 35: 2481-2482, 2003
37. Du C, Jiang J, Guan Q, Yin Z, Masterson M, Parbtani A, Zhong R, Jevnikar AM: Renal tubular epithelial cell self-injury through Fas/Fas ligand interaction promotes renal allograft injury. Am J Transplant 4: 1583-1594, 2004
38. Boonstra JG, van der Woude FJ, Wever PC, Laterveer JC, Daha MR, Van Kooten C: Expression and function of Fas (CD95) on human renal tubular epithelial cells. J Am Soc Nephrol 8: 1517-1524, 1997
39. Wever PC, Boonstra JG, Laterveer JC, Hack CE, van der Woude FJ, Daha MR, ten Berge IJ: Mechanisms of lymphocyte-mediated cytotoxicity in acute renal allograft rejection. Transplantation 66: 259-264, 1998
40. Schelling JR, Cleveland RP: Involvement of Fas-dependent apoptosis in renal tubular epithelial cell deletion in chronic renal failure. Kidney Int 56: 1313-1316, 1999
41. Cappellesso S, Valentin JF, Giraudeau B, Boulanger MD, Al Najjar A, Buchler M, Halimi JM, Nivet H, Bardos P, Lebranchu Y, Watier H: Association of donor TNFRSF6 (FAS) gene polymorphism with acute rejection in renal transplant patients: A case-control study. Nephrol Dial Transplant 19: 439-443, 2004
42. Du C, Wang S, Diao H, Guan Q, Zhong R, Jevnikar AM: Increasing resistance of tubular epithelial cells to apoptosis by shRNA therapy ameliorates renal ischemia-reperfusion injury. Am J Transplant 6: 2256-2267, 2006
43. Zheng X, Zhang X, Sun H, Feng B, Li M, Chen G, Vladau C, Chen D, Suzuki M, Min L, Liu W, Zhong R, Garcia B, Jevnikar A, Min WP: Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation 82: 1781-1786, 2006
44. Mohib K, Guan Q, Diao H, Du C, Jevnikar AM: Proapoptotic activity of indoleamine 2,3-dioxygenase (IDO) expressed in renal tubular epithelial cells. Am J Physiol Renal Physiol 293: F801-F812, 2007
45. Du C, Guan Q, Diao H, Yin Z, Jevnikar AM: Nitric oxide induces apoptosis in renal tubular epithelial cells through activation of caspase-8. Am J Physiol Renal Physiol 290: F1044-F1054, 2006
46. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC: IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17: 2215-2223, 1998
47. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784, 2003
48. Zeisberg M, Shah AA, Kalluri R: Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 280: 8094-8100, 2005
49. Grimm PC, Nickerson P, Jeffery J, Savani RC, Gough J, McKenna RM, Stern E, Rush DN: Neointimal and tubulo-interstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection. N Engl J Med 345: 93-97, 2001
50. Duffield JS, Park KM, Hsiao LL, Kelley VR, Scadden DT, Ichimura T, Bonventre JV: Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J Clin Invest 115: 1743-1755, 2005
51. Duffield JS, Bonventre JV: Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after ischemic injury. Kidney Int 68: 1956-1961, 2005
52. Eddy AA: Ramping up endogenous defences against chronic kidney disease. Nephrol Dial Transplant 21: 1174-1177, 2006
53. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R: BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964-968, 2003
54. Lin J, Patel SR, Cheng X, Cho EA, Levitan I, Ullenbruch M, Phan SH, Park JM, Dressler GR: Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med 11: 387-393, 2005
55. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: Pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12, 2004
56. Robertson H, Ali S, McDonnell BJ, Burt AD, Kirby JA: Chronic renal allograft dysfunction: The role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol 15: 390-397, 2004
57. McMorrow T, Gaffney MM, Slattery C, Campbell E, Ryan MP: Cyclosporine A induced epithehal-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant 20: 2215-2225, 2005
58. Slattery C, Campbell E, McMorrow T, Ryan MP: Cyclosporine A-induced renal fibrosis: A role for epithelial-mesenchymal transition. Am J Pathol 167: 395-407, 2005
59. Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF: Epithelial to mesenchymal transition during late deterioration of human kidney transplants: The role of tubular cells in fibrogenesis. Am J Transplant 5: 1367-1374, 2005
60. Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, Glotz D, Ancel PY, Rondeau E, Xu-Dubois Y: Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 6: 2937-2946, 2006
61. Drayton DL, Liao S, Mounzer RH, Ruddle NH: Lymphoid organ development: From ontogeny to neogenesis. Nat Immunol 7: 344-353, 2006
62. Kerjaschki D, Regele HM, Moosberger I, Nagy-Bojarski K, Watschinger B, Soleiman A, Birner P, Krieger S, Hovorka A, Silberhumer G, Laakkonen P, Petrova T, Langer B, Raab I: Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 15: 603-612, 2004
63. Thaunat O, Field AC, Dai J, Louedec L, Patey N, Bloch MF, Mandet C, Belair MF, Bruneval P, Meilhac O, Bellon B, Joly E, Michel JB, Nicoletti A: Lymphoid neogenesis in chronic rejection: Evidence for a local humoral alloimmune response. Proc Natl Acad Sci U S A 102: 14723-14728, 2005
64. Goto E, Honjo S, Yamashita H, Shomori K, Adachi H, Ito H: Mast cells in human allografted kidney: Correlation with interstitial fibrosis. Clin Transplant 16[Suppl 8]: 7-11, 2002
65. Ishida T, Hyodo Y, Ishimura T, Takeda M, Hara I, Fujisawa M: Mast cell numbers and protease expression patterns in biopsy specimens following renal transplantation from living-related donors predict long-term graft function. Clin Transplant 19: 817-824, 2005
66. Roberts IS, Brenchley PE: Mast cells: The forgotten cells of renal fibrosis. J Clin Pathol 53: 858-862, 2000
67. McKenna RM, Takemoto SK, Terasaki PI: Anti-HLA antibodies after solid organ transplantation. Transplantation 69: 319-326, 2000
68. Terasaki PI, Kreisler M, Mickey RM: Presensitization and kidney transplant failures. Postgrad Med J 47: 89-100, 1971
69. Susal C, Opelz G: Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation 73: 1269-1273, 2002
70. Terasaki PI, Ozawa M: Predicting kidney graft failure by HLA antibodies: A prospective trial. Am J Transplant 4: 438-443, 2004
71. Piazza A, Poggi E, Borrelli L, Servetti S, Monaco PI, Buonomo O, Valeri M, Torlone N, Adorno D, Casciani CU: Impact of donor-specific antibodies on chronic rejection occurrence and graft loss in renal transplantation: Posttransplant analysis using flow cytometric techniques. Transplantation 71: 1106-1112, 2001
72. Worthington JE, Martin S, Al Husseini DM, Dyer PA, Johnson RW: Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 75: 1034-1040, 2003
73. Supon P, Constantino D, Hao P, Cagle L, Hahn A, Conti DJ, Freed BM: Prevalence of donor-specific anti-HLA antibodies during episodes of renal allograft rejection. Transplantation 71: 577-580, 2001
74. Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL, Tsai A, Lei HY: All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 74: 1192-1194, 2002
75. Poggio ED, Clemente M, Riley J, Roddy M, Greenspan NS, Dejelo C, Najafian N, Sayegh MH, Hricik DE, Heeger PS: Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol 15: 1952-1960, 2004
76. Feucht HE, Felber E, Gokel MJ, Hillebrand G, Nattermann U, Brockmeyer C, Held E, Riethmuller G, Land W, Albert E.: Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 86: 464-470, 1991
77. Feucht HE, Schneeberger H, Hillebrand G, Burkhardt K, Weiss M, Riethmuller G, Land W, Albert E: Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 43: 1333-1338, 1993
78. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K: Antibody-mediated rejection criteria: An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3: 708-714, 2003
79. Mengel M, Bogers J, Bosmans JL, Seron D, Moreso F, Carrera M, Gwinner W, Schwarz A, De Broe M, Kreipe H, Haller H: Incidence of C4d stain in protocol biopsies from renal allografts: Results from a multicenter trial. Am J Transplant 5: 1050-1056, 2005
80. Lederer SR, Kluth-Pepper B, Schneeberger H, Albert E, Land W, Feucht HE: Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 59: 334-341, 2001
81. Habib R, Zurowska A, Hinglais N, Gubler MC, Antignac C, Niaudet P, Broyer M, Gagnadoux MF: A specific glomerular lesion of the graft: Allograft glomerulopathy. Kidney Int Suppl 42: S104-S111, 1993
82. Maryniak RK, First MR, Weiss MA: Transplant glomerulopathy: Evolution of morphologically distinct changes. Kidney Int 27: 799-806, 1985
83. Sijpkens YW, Joosten SA, Wong MC, Dekker FW, Benediktsson H, Bajema IM, Bruijn JA, Paul LC: Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 65: 2409-2418, 2004
84. Gloor JM, Sethi S, Stegall MD, Park WD, Moore SB, Degoey S, Griffin MD, Larson TS, Cosio FG: Transplant glomerulopathy: Subclinical incidence and association with alloantibody. Am J Transplant 7: 2124-2132, 2007
85. Regele H, Bohmig GA, Habicht A, Gollowitzer D, Schillinger M, Rockenschaub S, Watschinger B, Kerjaschki D, Exner M: Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 13: 2371-2380, 2002
86. Joosten SA, Sijpkens YW, van Ham V, Trouw LA, van der Vlag J, van den Heuvel B, van Kooten C, Paul LC: Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 5: 383-393, 2005
87. Akalin E, Dikman S, Murphy B, Bromberg JS, Hancock WW: Glomerular infiltration by CXCR3 + ICOS + activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant 3: 1116-1120, 2003
88. van den BJ, van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Berden JH: A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 41: 115-123, 1992
89. JJoosten SA, van Dixhoorn MG, Borrias MC, Benediktsson H, van Veelen PA, Van Kooten C, Paul LC: Antibody response against perlecan and collagen types IV and VI in chronic renal allograft rejection in the rat. Am J Pathol 160: 1301-1310, 2002
90. Ball B, Mousson C, Ratignier C, Guignier F, Glotz D, Rifle G: Antibodies to vascular endothelial cells in chronic rejection of renal allografts. Transplant Proc 32: 353-354, 2000
91. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schonemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 352: 558-569, 2005
92. Zou Y, Stastny P, Susal C, Dohler B, Opelz G: Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med 357: 1293-1300, 2007
93. Panigrahi A, Gupta N, Siddiqui JA, Margoob A, Bhowmik D, Guleria S, Mehra NK: Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss. Hum Immunol 68: 362-367, 2007
94. Cailhier JF, Laplante P, Hebert MJ: Endothelial apoptosis and chronic transplant vasculopathy: Recent results, novel mechanisms. Am J Transplant 6: 247-253, 2006
95. Shimizu A, Yamada K, Sachs DH, Colvin RB: Persistent rejection of peritubular capillaries and tubules is associated with progressive interstitial fibrosis. Kidney Int 61: 1867-1879, 2002
96. Adair A, Mitchell DR, Kipari T, Qi F, Bellamy CO, Robertson F, Hughes J, Marson LP: Peritubular capillary rarefaction and lymphangiogenesis in chronic allograft failure. Transplantation 83: 1542-1550, 2007
97. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]: 1-266, 2005
98. Meier-Kriesche HU, Baliga R, Kaplan B: Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 75: 1291-1295, 2003
99. Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 53: 217-222, 1998
100. Rahn KH, Barenbrock M, Fritschka E, Heinecke A, Lippert J, Schroeder K, Hauser L Wagner K, Neumayer H: Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: A randomised trial. Lancet 354: 1415-1420, 1999
101. van Riemsdijk IC, Mulder PG, de Fijter JW, Bruijn JA, van Hooff JP, Hoitsma AJ, Tegzess AM, Weimar W: Addition of isradipine (Lomir) results in a better renal function after kidney transplantation: A double-blind, randomized, placebo-controlled, multi-center study. Transplantation 70: 122-126, 2000
102. Madsen JK, Sorensen SS, Hansen HE, Pedersen EB: The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol Dial Transplant 13: 2327-2334, 1998
103. Midtvedt K, Hartmann A, Foss A, Fauchald P, Nordal KP, Rootwelt K, Holdaas H: Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 72: 1787-1792, 2001
104. Mourad G, Ribstein J, Mimran A: Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 43: 419-425, 1993
105. Hernandez D, Lacalzada J, Salido E, Linares J, Barragan A, Lorenzo V, Higueras L, Martin B, Rodriguez A, Laynez I, Gonzalez-Posada JM, Torres A: Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int 58: 889-897, 2000
106. Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn KH: ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 33: 862-868, 1999
107. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R: Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17: 889-899, 2006
108. Opelz G, Zeier M, Laux G, Morath C, Dohler B: No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: A collaborative transplant study report. J Am Soc Nephrol 17: 3257-3262, 2006
109. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361: 2024-2031, 2003
110. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3: 178-185, 2003
111. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69: 2405-2409, 2000
112. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11: 1910-1917, 2000
113. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B: Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353: 770-781, 2005
114. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, Gloor JM, Cosio FG, Lund WJ, Kremers WK, Nyberg SL, Ishitani MB, Prieto M, Velosa JA: Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 6: 514-522, 2006
115. Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ: Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 76: 120-129, 2003
116. Kaplan B, Schold J, Srinivas T, Womer K, Foley DP, Patton P, Howard R, Meier-Kriesche HU: Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant 4: 1709-1712, 2004
117. Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyo JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF: Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18: 22-28, 2005
118. Stallone G, Di Paolo S, Schena A, Infante B, Grandaliano G, Battaglia M, Gesualdo L, Schena FP: Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 75: 998-1003, 2003
119. Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, Hammond JA, Whisenant T, Lanigan CM, Head SR, Salomon DR: De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 4: 1776-1785, 2004
120. Groth CG, Backman L, Morales JM, Caine R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattstrom C, Charpentier B: Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67: 1036-1042, 1999
121. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattstrom C, Lebranchu Y, Vialtel P: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69: 1252-1260, 2000
122. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, Negre E, Burke JT, Groth CG: Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2: 436-442, 2002
123. Stallone G, Infante B, Schena A, Battaglia M, Ditonno P, Loverre A, Gesualdo L, Schena FP, Grandaliano G: Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 16: 3755-3762, 2005
124. Wali RK, Mohanlal V, Ramos E, Blahut S, Drachenberg C, Papadimitriou J, Dinits M, Joshi A, Philosophe B, Foster C, Cangro C, Nogueira J, Cooper M, Bartlett ST, Weir MR: Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 7: 1572-1583, 2007
125. Mannon RB: Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant 6: 867-875, 2006
126. Pihlajaniemi T, Myllyla R, Kivirikko KI: Prolyl 4-hydroxylase and its role in collagen synthesis. J Hepatol 13[Suppl 3]: S2-S7, 1991
127. Prockop DJ, Kivirikko KI: Collagens: Molecular biology, diseases, and potentials for therapy. Annu Rev Biochem 64: 403-434, 1995
128. Franceschini N, Cheng O, Zhang X, Ruiz P, Mannon RB: Inhibition of prolyl-4-hydroxylase ameliorates chronic rejection of mouse kidney allografts. Am J Transplant 3: 396-402, 2003
129. Lutz J, Yao Y, Song E, Antus B, Hamar P, Liu S, Heemann U: Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation 79: 655-661, 2005
130. Kuenzli S, Tran C, Saurat JH: Retinoid receptors in inflammatory responses: A potential target for pharmacology. Curr Drug Targets Inflamm Allergy 3: 355-360, 2004
131. Kiss E, Adams J, Grone HJ, Wagner J: Isotretinoin ameliorates renal damage in experimental acute renal allograft rejection. Transplantation 76: 480-489, 2003
132. Adams J, Kiss E, Arroyo AB, Bonrouhi M, Sun Q, Li Z, Gretz N, Schnitger A, Zouboulis CC, Wiesel M, Wagner J, Nelson PJ, Grone HJ: 13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy. Am J Pathol 167: 285-298, 2005
133. Azuma H, Takahara S, Matsumoto K, Ichimaru N, Wang JD, Moriyama T, Waaga AM, Kitamura M, Otsuki Y, Okuyama A, Katsuoka Y, Chandraker A, Sayegh MH, Nakamura T: Hepatocyte growth factor prevents the development of chronic allograft nephropathy in rats. J Am Soc Nephrol 12: 1280-1292, 2001
134. Mizui M, Isaka Y, Takabatake Y, Mizuno S, Nakamura T, Ito T, Imai E, Hori M: Electroporation-mediated HGF gene transfer ameliorated cyclosporine nephrotoxicity. Kidney Int 65: 2041-2053, 2004